2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5606 Clinicopathologic characterization of somatic CHEK2 mutations in hematopoietic neoplasms

Jinming Song, MD, PhD, Hailing Zhang, MD2, Lynn Moscinski, MD3, Xiaohong Zhao, MD, PhD4, Julie Li, MD5
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Background:

CHEK2 encodes a checkpoint kinase central to the ATM–CHK2–p53 DNA damage response axis. Existing data derive predominantly from germline-ascertained cohorts, while the somatic mutational landscape remains poorly characterized. We therefore performed a single-institution analysis of patients undergoing NGS for suspected myeloid neoplasms using a panel that includes CHEK2. To our knowledge, this study represents one of the largest single-center series. 

Methods and Materials:

Out of the Moffitt NextGen sequencing database of approximately 5157 patients, we identified 46 patients with CHEK2 somatic mutations, which excludes germline-range variant allele frequency (VAF)  of 45–55% or >90%, except for newly detected variants without prior history regardless of VAF. Overall survival (OS) was defined as the time from sequencing to the last visit at Moffitt or death. 

Results:

Of 5,157 patients, 46 (0.89%) harbored a somatic CHEK2 mutation. Sex distribution was even (23 female, 23 male), with a median age of 68.5 years. The median overall survival is 17.08 months (8.9-47.6). Clonal cytopenia of undetermined significance(CCUS) was the most common diagnosis (16/46, 34.8%, including 11 post cytotoxic CCUS-pCT), followed by acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) (n=10, 21.7% each), MDS-MPN overlap (n=5, 10.9%), and single cases of chronic lymphocytic leukemia, multiple myeloma, systemic mastocytosis, hairy cell leukemia, and post-transplant patient (n=5, 13.0%). In this cohort, 15 patients (33%) had a documented history of prior cytotoxic therapy (pCT) for an antecedent malignancy, most commonly plasma cell neoplasm (PCN) (6/15 pCT patients, 40%; 6/11 CCUS-pCT cases, 55%). CCUS was significantly enriched among PCN (83%, 5/6) compared to those without (28%, 11/40; p value 0.015, OR 13.2).

The median CHEK2 VAF across the cohort was 8.25% (range 2.6–66.6%). The majority of patients (34/46, 74%) had a VAF <=15%, a range most consistent with a low-burden acquired clone in the setting of clonal hematopoiesis. Only 9 of 46 patients (20%) had CHEK2 as the sole detectable mutation (VAF >=2%). The most frequently co-mutated genes were DNMT3A (21.7%), ASXL1 (17.4%), JAK2 (15.2%), TET2 (13.0%), RUNX1 (8.7%), and TP53 (8.7%), supporting CHEK2 acting largely as a cooperating or passenger-like lesion, consistent with prior reports that CHEK2 predisposes to and co-occurs with clonal hematopoiesis rather than serving as a primary leukemic driver. Patients with pCT had lower CHEK2 VAF and fewer co-mutated genes. This pattern is consistent with closer post-treatment surveillance catching these DNA-damage-response–selected clones earlier and smaller.

Interestingly, patients with co-mutation of JAK2 showed significantly better overall survival (OS) by Kaplan-Meier analysis (p value 0.0455), while the median OS time is also much longer than patients without JAK2 co-mutations (38.03 vs 14.33 months, p value 0.06386). As expected, patients with a diagnosis of post cytotoxic treatment myeloid neoplasms showed worse median OS time than patients without (11.8 vs 23.07 months, p value 0.04267).

Discussion:

CHEK2 mutations were identified in 0.89% of patients, confirming that somatic CHEK2 alterations, while uncommon, are not negligible in routine clinical sequencing. The predominance of low-VAF clones and the low rate of CHEK2 as a sole mutation support a model in which CHEK2 loss most often arises as a cooperating lesion within a broader clonal hematopoiesis background rather than as a primary disease driver. This is reinforced by the co-mutation landscape, dominated by canonical age-related clonal hematopoietic genes (DNMT3A, ASXL1, TET2) alongside JAK2. 

A history of prior cytotoxic therapy was common, particularly among patients with an antecedent plasma cell neoplasm, in whom CCUS was significantly enriched. Notably, pCT-associated clones had lower VAF and fewer co-mutations, likely reflecting earlier detection through intensive post-treatment surveillance.

Among co-mutations, JAK2 was associated with significantly improved OS, suggesting that CHEK2 mutations arising on an MPN background may behave differently — and more favorably — than those arising in the setting of myelodysplastic or therapy-related clonal evolution. Larger, prospective, multi-institutional cohorts  are needed to clarify the independent prognostic contribution of CHEK2.
Jinming Song, MD, PhD: No relevant conflicts of interest to declare.